• Janet M Leeds, Frederique Fenneteau, Nathalie H Gosselin, Mohamad-Samer Mouksassi, Nastya Kassir, J F Marier, Yali Chen, Doug Grosenbach, Annie E Frimm, Kady M Honeychurch, Jarasvech Chinsangaram, Shanthakumar R Tyavanagimatt, Dennis E Hruby, and Robert Jordan.
• SIGA Technologies, Corvallis, OR, USA.
• Antimicrob. Agents Chemother. 2013 Mar 1; 57 (3): 1136-43.

AbstractAlthough smallpox has been eradicated, the United States government considers it a "material threat" and has funded the discovery and development of potential therapeutic compounds. As reported here, the human efficacious dose for one of these compounds, ST-246, was determined using efficacy studies in nonhuman primates (NHPs), together with pharmacokinetic and pharmacodynamic analysis that predicted the appropriate dose and exposure levels to provide therapeutic benefit in humans. The efficacy analysis combined the data from studies conducted at three separate facilities that evaluated treatment following infection with a closely related virus, monkeypox virus (MPXV), in a total of 96 NHPs. The effect of infection on ST-246 pharmacokinetics in NHPs was applied to humans using population pharmacokinetic models. Exposure at the selected human dose of 600 mg is more than 4-fold higher than the lowest efficacious dose in NHPs and is predicted to provide protection to more than 95% of the population.

35 keywords...

hide…